Seonix Bio provides a genetic risk score service, SightScore™, that utilizes saliva-based testing to assess an individual's polygenic risk of developing glaucoma. This service equips eye health professionals with clinically relevant genetic information to identify patients at risk and inform their monitoring and treatment strategies.
Funding
Funding not disclosed
Founders
Product
Problem
Glaucoma, a progressive eye disease often causing gradual vision loss, poses a challenge for early detection and proactive management due to its polygenic nature and the limitations of traditional single-gene testing methods. Identifying individuals at high risk of developing glaucoma or experiencing disease progression remains a critical unmet need in ophthalmology.
Solution
Seonix Bio offers SightScore™, a genetic risk score service that utilizes a saliva-based test to evaluate an individual's polygenic risk for glaucoma. By analyzing thousands of genetic variants associated with glaucoma, SightScore™ provides clinicians with a comprehensive risk assessment to inform monitoring and treatment strategies. The test results help healthcare professionals identify at-risk patients who may benefit from earlier or more frequent monitoring, allowing for timely intervention and personalized management plans. SightScore™ is designed to complement existing clinical assessments and improve the accuracy of glaucoma risk prediction.
Target Audience
The primary target audience includes ophthalmologists, optometrists, and other eye care professionals who seek to improve glaucoma risk assessment and personalize patient management strategies. SightScore™ is also available for asymptomatic individuals with a family history of glaucoma who wish to understand their risk.
Features
- Saliva-based DNA collection for convenient and non-invasive sample acquisition
- Analysis of thousands of genetic variants associated with glaucoma risk
- Proprietary algorithms to calculate a personalized genetic risk score
- Clinically relevant risk stratification to guide monitoring and treatment decisions
- Integration of genetic risk information with other clinical factors for comprehensive assessment
- Secure online portal for clinicians to access and interpret test results
- Available in the United States, Australia, and New Zealand